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Pineoblastoma (PB) are rare, aggressive pediatric brain tumors of the pineal gland with modest 
overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB 
to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 
patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 
pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in 
the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group 
of PB from 72/93 cases, which were delineated into five molecular subgroups. Copy number, whole 
exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-
pathologic significance of each subgroup. Tumors designated as group 1 and 2 almost exclusively 
exhibited deleterious homozygous loss of function alterations in miRNA biogenesis genes (DICER1, 
DROSHA, and DGCR8) in 62 and 100% of group 1 and 2 tumors respectively. Recurrent alterations of 
the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC subgroup, 
respectively characterized by RB1 loss with gain of miR-17/92, and recurrent gain or amplification of 
MYC. PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 
5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB 
and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 
37.5% and 28.6%, respectively). We identified age <3 years at diagnosis, metastatic disease, omission 
of upfront radiation, and chr 16q loss as significant negative prognostic factors across all PBs. Our 
findings demonstrate that PB exhibit substantial molecular heterogeneity with sub-group associated 
clinical phenotypes and survival. In addition to revealing novel biology and therapeutics, molecular 
sub-grouping of PB can be exploited to reduce treatment intensity for patients with favorable biology 
tumors. 
Keywords: pineoblastoma, PNET, PPTID, miRNA, RB, MYC  




Malignant brain tumors are the leading cause of pediatric cancer-related death and disability. 
Embryonal brain tumors (EBTs) are the largest group of brain tumors diagnosed in children 0-14 years 
old and comprise 20% of all pediatric brain neoplasms [47]. Although historically classified based on 
tumor location and similar primitive neuroectodermal tumor (PNET) histology [24], EBTs are known 
to comprise a spectrum of molecular diseases with distinct clinico-pathologic features [8]. 
Medulloblastoma (MB) which represents 60% of childhood EBTs has been most studied, while rare 
EBTs, which comprise ~40% of EBTs are understudied and poorly understood. These include atypical 
rhabdoid/teratoid tumors (ATRTs), embryonal tumors with multilayered rosettes (ETMRs), as well as 
pineoblastoma (PB) - all historically treated as high-risk brain tumors with intensified regimens 
[30,29].  
PBs comprise 30% of all pineal region tumors and may be difficult to distinguish from other 
tumors including germ cell tumors, high-grade gliomas, ATRTs, ETMRs and lower-grade pineal 
parenchymal tumors of intermediate differentiation (PPTIDs) [32]. PB have been grouped in clinical 
and biological studies with other EBTs arising in cerebral locations, called supratentorial primitive 
neuro-ectodermal tumors (sPNETs or CNS-PNETs) [42]. As there are few dedicated PB studies, the 
clinical and molecular spectra, and best treatment approach for these highly malignant tumors remains 
to be established. A recent large clinical retrospective study indicated radiotherapy (RT) but not high-
dose chemotherapy (HDC) improved survival of PB patients ≥4 years old [45], although prospective 
consortia studies show improved survival for older children with intensified multi-modal approaches 
[29,27,11]. Historical sPNET studies also reported 5-yr OS of 50-65% for older children with pineal 
region EBTs, while patients < 3-5 years old had poorer 5-yr OS of 15-40% [30,20]. Whether these 
observations reflect age-related treatment biases or biological differences remain unknown. 
Limited animal modeling data [57] and clinical studies of heritable “tri-lateral” retinoblastoma 
[14,6] suggest a role for RB1 and related tumor suppressor pathways in PB. In addition, miRNA 
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biogenesis gene defects have also been recently implicated in PBs [15,58]. MiRNAs which are critical 
post-transcriptional regulators, undergo complex processing by endonucleases (DROSHA, DGCR8, 
and DICER1) into mature miRNAs that function in RNA-induced silencing complexes (RISC) [37]. 
Although, several small studies have reported DICER1 and DROSHA alterations in PB, the spectrum of 
RB and miRNA biogenesis alterations and their clinical significance in PBs remains to be fully 
evaluated. In this study, we integrated global DNA methylation profiling, copy number, and whole 
exome (WES) and targeted sequencing analyses on a large cohort of PB patients enrolled in a rare brain 
tumor registry to investigate the molecular and clinic-pathologic spectrum of PB. 
 
Materials and Methods 
Tumor, blood, and clinical data 
Tumor tissue, blood, and clinical data from 93 patients diagnosed with PB, related 
sPNETs/CNS-PNETs, or PPTID were collected from 29 centres as part of the global Rare Brain Tumor 
Consortium biorepository and clinical registry (rarebraintumorconsortium.ca) using procedure 
approved by Research Ethic Board at the Hospital for Sick Children and participating institutions 
(Supplementary Table 1, online resource) . All cases were diagnosed at their referring institutions. 
Available pathology reports and prepared slides were all reviewed by an experienced pediatric 
neuropathologist. Six of these cases have previously been analyzed by Affymetrix 100K single-
nucleotide polymorphism (SNP) array and reported by Miller et al.[42]. DNA from frozen tissue or 
formalin-fixed, paraffin-embedded materials, and blood were extracted using the Qiagen AllPrep 
DNA/RNA Mini kit (Qiagen, Germany), and total RNA from 6 tumors was prepared with nCounter 
miRNA prep kit according to standard protocol. 
 
Molecular and bioinformatic analyses 
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Tumor DNA was analysed on the Illumina HumanMethylation450 or MethylationEPIC 
methylation arrays (Illumina, San Diego, CA) as described previously (www.tcag.ca) [64,59] and 
5000-15,000 most variable probes (standard deviation >0.3) were used for all downstream analyses (R 
v3.3.1). Tumor types were determined using unsupervised cluster analyses of methylation data against 
1200 reference tumor profiles [59]. 
For t-distributed stochastic neighbor embedding, default parameters were used, except for 
perplexity = 10 (Rtsne v0.15, R v3.5.3). For hierarchal clustering, 1-Pearson correlation was used for 
distance measuring, with average linkage (pheatmap R package, R v3.61). k-means clustering was 
performed with Euclidean for distance measuring, and average linkage (ConsensusClusterPlus R 
package). Non-matrix factorization (NMF) analysis was performed with ranks (k) 2-10 at 100 runs 
(NMF v0.20.6). Tumor copy number profiles were determined using Conumee (version 1.8.0) and 
GISTIC2 (v2.0.23) [41] analyses on methylation and Illumina Omni SNP array. 
WES analysis was performed on the Illumina HiSeq 4000 platform (Genome Quebec, TCAG), 
with variant calling using the Mutek2 pipeline (Ontario Institute for Cancer Research). Targeted 
sequencing was performed on the Ion Torrent platform using custom primers (Thermo Fisher 
Scientific) and the Ion Reporter variant calling pipeline (Genome Quebec, ResourcePath) [41]. 
Mutations were called deleterious or potentially deleterious based respectively on calls by both or one 
of the Sorting Intolerant From Tolerant (SIFT) (<0.05) or Polyphen-2 (>0.909) tool scores [66,1].  
MiRNA expression was determined based on the NanoString miRNA panel (NanoString Technologies 
Inc.) [59] for available tumor-derived miRNA.  
 
Statistical analyses 
Event-free survival (EFS) was defined as interval between time of diagnosis to first event: tumor 
recurrence or progression, death from any cause, or last follow-up for those without events. Overall 
survival (OS) was defined as interval between time of diagnosis and death from any cause or last 
Pineoblastoma segregates into molecular sub-groups 
8 
 
follow-up. Survival and prognostic factor analyses were performed on cases treated with curative intent 
and for which complete treatment and outcome information were available. Survival estimates were 
performed using Kaplan-Meier method with 95% CI, with log-rank testing used for comparisons. 
Fisher exact and Kruskal-Wallis analyses were used to evaluate association of specific clinical features 
(age, tumor location, stage) with PB sub-groups, while univariate Cox proportional hazards regression 
modelling was used to identify clinical and treatment prognostic factors. All statistical analyses were 
performed in R v3.6.1. 
 
Results 
PB segregates into five molecular subgroups with distinct copy number profiles 
Global methylation data from 93 tumors diagnosed as PB, sPNETs/CNS-PNETs, or PPTID 
were analysed against a reference cohort of 1200 pediatric brain tumors [59] using unsupervised 
orthogonal clustering (t-distributed stochastic neighbour embedding, NMF, K-means and hierarchal 
clustering) analyses (Fig. 1a, b). Attributable to the difficulty in diagnosing PB, 21/93 cases clustered 
with other tumor entities (11 germ cell tumor, 5 ATRTs, 2 MB, 2 high-grade glioma, 1 ETMR), and 
were excluded from further analysis. The remaining 72 tumors which segregated in one distinct cluster 
were further characterized using NMF, hierarchal clustering, and K-means clustering which revealed 5 
robust sub-groups with highest co-phenetic co-efficient score at k=5 (Supplementary Fig. 1, online 
resource). We designated these as group 1, 2, 3, RB, and MYC PB sub-groups, respectively consisting 
of 21, 11, 13, 9, and 18 tumors, based on specific copy number and mutational features described 
below.  
To further investigate PBs sub-groups, we performed copy number analyses using Conumee 
and GISTIC2 analyses on methylation and SNP array data (Fig. 2a), which revealed few significant 
overlapping copy number alterations except for chr 16 loss seen in all but group 3 PBs. Group 1 tumors 
most frequently exhibited broad gains of chr 7 (5/21; 24%) and chr 12 (6/21; 29%) and losses of chr 16 
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(5/21; 24%) and 22q (6/21; 29%). More detailed analysis revealed 14% (3/21) of group 1 tumors 
exhibited recurrent loss of a minimal 1.4Mb region on chr 5p13.3 encompassing DROSHA, which 
mediates primary-miRNA processing (Fig. 2b). In group 2 tumors, DNA methylation (Fig. 2c) and 
SNP array (Supplementary Fig. 2a, online resource) data showed broad chr 14q (9/11; 82%) losses 
where miRNA endonuclease gene DICER1 maps, and focal homozygous DROSHA loss in one sample. 
Additionally, group 2 tumors exhibited loss of chr 8 (5/11; 45%), 16 (3/11; 27%), and 20 (3/11; 27%). 
In contrast, group 3 PB had no significant recurrent copy number alterations except for chr13q loss in 
3/13 (23%) samples (Fig. 2d).  
In the fourth designated RB sub-group, methylation and SNP arrays showed recurrent losses of 
a focal 0.6Mb chr 13q14.2 region spanning RB1 in 56% (5/9) of samples (Fig. 3a; Supplementary Fig. 
2b, online resource); 80% (4/5) of these also harbored focal gains of a 1.9Mb chr13q13.3 region 
spanning the miR-17/92 oncogene previously implicated in retinoblastoma [12]. Nanostring expression 
profiling on a cohort of 6 primary PBs indicated copy number driven miR-17/92 expression in a group 
RB PB (RBTC746), without significant changes in expression of paralogous loci, miR-106b/25 and 
miR-106a/363, or the unrelated let-7 locus (Fig. 3b). The RB sub-group also exhibited broad chr 1q 
(3/9; 33%) and 6p (5/9; 55%) gains and chr 16 losses (7/9; 78%) (Fig. 3a). The fifth sub-group, 
designated as the MYC PB, exhibited recurrent focal gains (7/18; 39%) or amplification (2/18; 11%) of 
a 1.2 Mb chr 8q24.21 segment encompassing MYC and chr 16q losses (8/18; 44%) (Fig. 3c).  
 
miRNA biogenesis defects, RB1 loss, and MYC activation characterize PB sub-groups  
To extend our copy number analyses we performed WES for 11 samples and targeted 
sequencing of DICER1, DROSHA, DGCR8, XPO5, TARBP2, RB1, and TP53 for 48 tumor and 21 
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matched blood samples with limited materials; 2 additional tumors and 2 blood samples only had 
materials sufficient for targeted DICER1 and TP53 sequencing only.  
 Sequencing analyses revealed mutually exclusive recurrent, deleterious, loss of function 
mutations of DICER1, DROSHA, or DGCR8 almost exclusively in group 1 and 2 PBs (Fig. 4a). 
Significantly 11/15 DICER1, 6/8 DROSHA and 3/3 DGCR8 alterations were novel cancer mutations 
not reported in COSMIC (https://cancer.sanger.ac.uk/cosmic) (Table 1). Of 15 unique DICER1 
mutations in 16 PBs, 11 were nonsense/frameshift and 4 were missense mutations. Truncating DICER1 
mutations were located within or prior to the RNase IIIb domain, while missense mutations mapped to 
the RNase IIIb and Helicase domains. DROSHA mutations, which were distributed throughout the 
gene, were also predominantly truncating (5/8), while only 1/3 DGCR8 mutations was predicted to be 
truncating. Less common alterations included two novel, potentially deleterious missense mutations of 
XPO5, which functions in pre-miRNA export. No alterations in TARBP2, a DICER miRNA loading 
complex gene, mutated in a spectrum of cancers [21,16], were seen in our PB cohort. Significantly, we 
also identified germline DICER1 mutation in 5 patients and a potential deleterious missense germline 
DROSHA mutation (RBTC717, c.199C>A; p.P67T) in one patient. Of note, all DICER1 mutations in 
group 1 (6/6) and 2 (9/9) PBs were accompanied by deleterious somatic DICER1 mutations or 
heterozygous chr 14q loss, variant allele frequency >96%, or complete chr14q loss. Similarly, three 
tumors with DGCR8 mutations, both in groups 1 and 2 PBs, also exhibited chr 22q loss. Collectively 
our data shows critical miRNA biogenesis genes are targeted by copy number alterations and/or 
mutations in 62 (13/21) and 100% (11/11) respectively of group 1 and 2 PBs (Fig. 4). 
 Targeted sequencing of ten group 3 PB did not reveal any miRNA biogenesis genes, RB1 or 
TP53 alterations. Interestingly, additional WES analyses of group 3 PB samples revealed 2/8 
(RBTC786 and -793) harbored similar in-frame insertions (c.935_936insCGTGGG and  
c.937_938insGCCGTG, respectively) in KBTBD4, which encodes a Cul3 E3 ubiquitin ligase adaptor, 
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resulting in a p.P311_R312dup affecting the Kel substrate binding domain (Supplementary Fig. 3, 
online resource) [7]. While the c.937_938insGCCGTG mutation has recently been proposed to be a 
marker for PPTIDs [35], both cases of PPTID in our cohort, which were group 3 tumors, did not have 
this alteration on WES [18]. While both our tumors with this mutation were institutionally diagnosed as 
PB, they had lower Ki67 labeling indices (Supplementary Table 2, online resource) more consistent 
with PPTID based on values reported by Fèvre-Montange et al. [18]. Examining all group 3 tumors 
diagnosed as PB, Ki67 scores were at the threshold between PPTID and PB (mean 19.2%, range 10-
40%). In total, group 3 tumors (mean 16.6%, range 3-40%) had significantly lower Ki67 scores than 
tumors belonging to other groups (mean 39.6%, range 10-75%) (p=0.003 by Kruskal-Wallis test). 
In contrast to group 1 and 2 tumors, sequencing of 22 RB and MYC sub-group PBs revealed 
only two potentially deleterious DICER1 mutations without evident LOH, one each in a MYC 
(RBTC779, c.1468N>T; p.R490C) and a RB subgroup (RBTC758, c.5240C>T; p.S1747L) tumor. 
Consistent with copy number analyses, sequencing revealed 3/8 (38%) RB sub-group tumors had 
recurrent stop-gain RB1 (p.R320* and p.Q121*) mutations previously reported in other cancers 
including retinoblastoma [39,22]. Amongst the RB subgroup patients, one (RBTC1231) presented in 
the context of tri-lateral retinoblastoma for which confirmatory germline testing could not be 
performed. Targeted sequencing of 21 blood samples, including 5 from RB subgroup patients, did not 
reveal any additional RB1 germline mutations. Notably, we did not identify somatic or germline TP53 
mutations in 48 PBs and 10 matched blood DNA samples sequenced.  
PB subgroups have distinct clinico-pathologic features  
Although PB predominantly arises in children, we observed a wide range of ages from six 
months to 60 years among 61/72 patients with available data, with 87% of patients <18 yrs of age, and 
children <3yrs comprising 28% of all patients (Supplementary Table 3, online resource).  Comparison 
of clinical features showed no gender bias in the entire cohort (p=0.127) although, there was a 
Pineoblastoma segregates into molecular sub-groups 
12 
 
predominance of females and males respectively in the RB (1 male:3.5 female) and MYC (2.6 male: 1 
female) group of patients (Table 2).  While children with group 1-3 PBs had respective median ages of 
5.2, 12.5, and 14.0 years at diagnosis, the RB and MYC group patients were much younger with 
median ages of 1.3 and 1.4 years respectively (p<0.0001) (Fig. 5a). Staging data available for 54 
patients indicated 39% (21/54) of primary PB were metastatic; 20/21 patients presented with M3/M4 
disease, and only one with M1 disease. Incidence of metastases at diagnosis differed significantly 
across PB groups (p= 0.028) with group 2 and RB group patients respectively exhibiting the lowest 
(13% M2; 1/8 patients) and highest incidence (100% M3; 5/5 patients) of metastases (Fig. 5b).   
46/72 PB patients were treated with curative intent and had complete treatment and outcome 
information available (Table 2). Univariate analyses revealed age <3yrs as a significant negative 
prognostic factor for EFS (HR 3.1, CI 1.3-7.4, p=0.008) and OS (HR 3.8, CI 1.4-10.1, p=0.008).  EFS 
(HR 2.7, CI 1.2-6.3; p=0.017) and OS (HR 3.6, CI 1.3-9.7, p=0.012) were also significantly inferior in 
patients with metastatic disease at diagnosis. Patients who did not receive upfront RT also had inferior 
EFS (HR 6.5, CI 2.7-15.6, p<0.001) but not OS (HR 2.3, CI 0.8-6.7, p=0.115), while receipt of 
conventional chemotherapy only vs. HDC, and extent of surgery were not significantly associated with 
EFS or OS. As PB patients <3yrs are often treated without RT or with delayed RT regimens, we also 
examined prognostic factors stratified by age <3 and ≥3yrs at diagnosis. These analyses showed no 
significant prognostic factors except a trend toward poorer EFS with conventional dose chemotherapy 
compared to HDC among 11 children <3yrs, while metastatic disease remained a significant negative 
prognostic factor for OS (HR 4.3; 95% CI 1.1-16.7; p=0.035) but not for EFS in children >3yrs of age 
at diagnosis.  
Kaplan-Meier survival analyses for all PB patients treated with curative intent revealed 5-yr 
EFS and OS respectively of 48.1 and 65.0%. Consistent with our Cox proportional hazards regression 
model, patients < 3 yrs, metastatic disease at diagnosis, and who were not treated with upfront RT had 
significantly poorer survival. The 5-yr EFS and OS for patients stratified by ≥ 3 vs. < 3 yrs of age were 
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58.2% vs. 18.2% (p=0.005) and 77.0% vs. 24.2%, (p=0.005) respectively (Supplementary Fig. 4a, 
online resource), while patients with localized and metastatic disease had 5-yr EFS and OS of 60.5% 
vs. 29.4% (p=0.012) and 78.7% vs. 44.8% (p=0.008) respectively. Patients treated with and without 
upfront RT had respective 5yr EFS of 58.8% vs 10% (p<0.0001), while upfront RT was also associated 
with a trend towards improved survival: 5-yr OS for patients who received upfront RT was 71% vs. 
40% for patients who did not receive upfront RT (p=0.106) (Supplementary Fig. 4b-c, online resource).  
In addition to clinical risk factors, our analyses indicated PB survival also correlated with 
molecular features of tumors. Notably, EFS differed significantly across the five molecular subgroups 
of PB (p=0.009) while OS trended toward significance (p=0.096), with group 2 PB patients exhibiting 
a striking 100% 5-yr EFS/OS (Fig. 5d). In contrast, the RB and MYC sub-groups of PB, which 
correlated with youngest age at diagnosis and highest frequency of chr 16q loss, had the lowest 5-yr 
EFS/OS of only 25%/37.5% and 14.3%/28.6%, respectively (Table 2). Because chr 16q loss was 
associated with these high-risk groups but also seen recurrently in groups 1 and 2, we analyzed whether 
it was independently associated with poorer outcomes. Indeed, across all cases, those with chr 16q loss 
compared to unaltered chr 16q were associated respectively with 16.1% vs. 63.0% 5yr-EFS (p=0.015) 
while OS were respectively 47.0% vs. 72.4% (p=0.139) (Supplementary Fig. 5, online resource). 
Collectively our data suggest distinct tumor biology are associated with different clinical risk features 
and may contribute significantly to disparate treatment-related outcomes in PBs. 
 
Discussion  
PBs are high-risk brain tumors with only modest long-term survival despite multi-modal 
intensive regimens and for which there remains limited data to inform novel therapeutic approaches 
[20,29,45,27,11]. Here we performed an integrated molecular and clinic-pathologic analyses of a large 
cohort and demonstrate PBs comprise 5 molecular sub-groups with distinct clinico-pathologic and 
survival features. Group 1 and 2 PB which arise in older children exhibit recurrent miRNA biogenesis 
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gene defects; group 3 PB which affects adolescents and adults exhibit few alterations, while the RB and 
MYC sub-groups affecting children age <18 months harbor RB1 and MYC alterations. Our data 
indicate age <3yrs, metastases at diagnosis and tumor molecular features as important determinants of 
survival in PB patients (summarized in Fig. 6) and provide an important framework for prospective 
studies.  
Strikingly, we identified deleterious mutations in multiple components of the miRNA 
processing machinery almost exclusively in group 1 and 2 PBs. Consistent with association of PBs 
with DICER1 predisposition syndrome [15,58], we identified germline and somatic DICER1 mutations 
in addition to somatic DROSHA and DGCR8 mutations, which have not been reported in PBs to date. 
With the exception of reported nonsense mutations [15] in RBTC717 and -745, all of the DICER1 
mutations identified in our study were novel and those in group 1 PB most commonly affected the 
RNase IIIb domain which selectively processes 5p miRNA [26]. Interestingly, imbalanced abundance 
of 5p versus 3p miRNAs due to RNase IIIb domain mutations have been implicated as important 
oncogenic mechanisms [28,3,53]. In contrast, mutations in group 2 tumors affecting both RNase 
domains were predicted to completely impair miRNA maturation, as reported in Wilm’s tumors [54]. 
Group 1 and 2 PBs with DICER1 mutations exhibited LOH as reported in smaller PB studies [15,58]. 
This is in stark contrast to DICER1 mutations in other tumors, where LOH is rare and truncating 
germline mutations are associated with hotspot missense mutation of the RNase IIIb domain [19]. In 
PBs, the second hit appears to be either chr 14q loss or a second truncating mutation of both RNase 
domains. Interestingly, murine tumors with bi-allelic Dicer1 knockout appear to be selected against 
[33] suggesting PB tumors likely retain some residual DICER1 activity, either through conserved 
RNase IIIa domain (in group 1) or other aberrant functions not involving the RNase domains (in group 
2). The unique pattern of DICER1 somatic and germline mutations observed in our cohort suggest 
specificity of the second hit in the formation of this tumor. 
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We identified truncating and damaging missense mutations of both DROSHA and DGCR8, but 
at much lower frequency than DICER1. As these mutations were seen only in group 1 and 2 PBs, and 
in only 10% (6/59) of tumors in our study, it is perhaps not surprising that DROSHA and DGCR8 
mutations were not reported in recent WES or whole genome sequencing studies of 19 PBs [60,35]. 
DROSHA mutations are frequent in Wilm’s tumors, where > 70% are missense mutations at E1147 in 
the RNase IIIb domain [68,67]. Although the IIIa and b domains respectively processes the 3p and 5p 
arms of pri-miRNA, the reported missense mutations do not appear to cause an imbalance in 5p and 3p 
mature miRNAs, but may act via dominant-negative mechanisms to globally downregulate miRNA 
production [54,65]. Our findings suggest miRNA maturation may also be globally downregulated in a 
subset of group 1 and 2 PBs via homozygous loss or biallelic truncating mutations of several critical 
miRNA endonucleases. All DGCR8 mutations in our PB samples were accompanied by chr 22 loss or 
LOH, similar to LOH in Wilms tumors with hotspot DGCR8 dsRBD mutations that impair mature 
miRNA expression [65,67,68]. Interestingly, one group 1 PB (RBTC757) exhibited loss of chr 22 copy 
in the context of the chr 22q11.2 deletion syndrome (22q11.2DS, DiGeorge syndrome). The minimal 
chr 22q11.2DS region which encompasses DGCR8 has also been linked to two prior cases of PB 
[46,61,34], and suggest DGCR8 loss may predispose to PB. 
Although heritable retinoblastoma is associated with increased risk for PB [43], RB1 alterations 
have not been described in sporadic PB. In the RB subgroup, we observed recurrent RB1 homozygous 
loss or inactivating stop-gain mutation with LOH consistent with a classic two-hit mechanism. 
Associated with RB1 loss, we observed recurrent copy number gains of chr 13q31.3 which 
encompasses the oncogenic miR-17/92 cluster. In Rb/p107-deficient mice, miR-17/92 overexpression 
drives retinoblastoma formation by targeting Cdkn1a (p21/Cip1) to increase retinal cell proliferation 
[12], an oncogenic process that requires intact Dicer1 function [48] and may explain the paucity of 
miRNA biogenesis gene mutations in the RB sub-group of PBs. Of note we observed that MYC, which 
is also known to drive neoplastic growth by upregulating miR-17/92 [36], was recurrently 
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gained/amplified in the MYC PB sub-group. These observations suggest common oncogenic 
mechanisms driven by a MYC-miR-17/92-RB1 axis [55,56] may underlie the aggressive biological 
features seen in these PB subgroups 
 KBTBD4 is a member of a large family of Bric-a-brac/Tramtrack/Broad (BTB) complex-
containing adaptor proteins that complex with CUL3 E3 ubiquitin ligase and serve as a bridge between 
CUL3 and its substrate via a kelch interaction domain [10,7]. Substrates are then ubiquitinated and 
marked for degradation in the ubiquitin proteasome pathway. Hotspot mutations affecting the kelch 
domain have been reported in group 3 and 4 MB [49], and three cases of PPTID [35], and have been 
proposed as an oncogenic driver. While the targeted substrate of KBTBD4 has not been demonstrated, 
similar mutations in other BTB proteins that affect the substrate-binding domain or cause loss-of-
function have been reported in a variety of cancers [10]. For example, in prostate cancer, androgen 
receptor signaling is implicated in tumor initiation and progression, as well as development of 
resistance to anti-androgen therapy [9]. Mutations affecting the androgen receptor-binding domain of 
BTB protein SPOP [5] leads to the failure of ubiquitination by CUL3 and thus, enhanced androgen 
receptor signaling [2]. Our WES analyses identified hotspot kelch domain mutations in 2/8 sequenced 
group 3 tumors. Although both these cases, diagnosed as PB, had lower Ki67/MIB-1 proliferation 
indices more consistent with PPTIDs [18], we did not observe this alteration in our two cases of PPTID 
or other group 3 PBs. While the hotspot KBTBD4 mutation have been proposed to be a marker for 
PPTID [35], our data suggests this mutation is characteristic for at least some group 3 tumors rather 
than exclusively all PPTIDs. With the caveat that Ki67/MIB-1 scores can be subjective and variable 
depending on tumor sample size, our review of scores in our cohort suggest group 3 is mainly 
composed of PBs with lower Ki67 indices in the range of PPTIDs, and tumors diagnosed as PPTIDs. 
Thus, tumors diagnosed as PPTID may be biologically similar to a proportion of PBs based on their 
shared global DNA methylation profile and silent chromosomal copy number landscape. Alternatively, 
some PPTIDs may be mis-diagnosed as PBs. 
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We observed on univariate analysis that loss of chr 16q was a significant negative prognostic 
marker for EFS and trending toward significance for OS. Interestingly, in another childhood embryonal 
cancer, Wilm’s tumor, chr 16q loss is also an established independent negative prognostic marker for 
relapse and death, and is being used to risk stratify patients with favorable histology tumors for 
intensified therapy [25]. Whether the loss-of-heterozygosity (LOH) of chr 16q disrupts a putative tumor 
suppressor or is a result of greater genomic instability remains to be elucidated for Wilm’s tumor. 
Some groups have proposed that LOH 16q may involve the effects of tumor-associated genes E2F4, 
COX4 [50], and CTCF [44], which all reside on chr 16q. We did not see mutations affecting these 
genes in our limited WES. 
 However, RB family tumor suppressor RBL2 (p130) also resides on 16q and is inactivated or 
lost in multiple cancers, including retinoblastoma [4,62,13,69,52]. We found that group RB and MYC 
tumors are characterized by chr 16q loss and an oncogenic MYC-miR-17/92-RB1 axis. Interestingly, in 
pancreatic adenocarcinoma, high expression of one member of the miR-17/92 cluster, miR-17-5p, 
directly targets RBL2 to inhibit RBL2-mediated repression of E2F4 target genes (MYC, CCND1, JUN), 
thereby enhancing proliferation [69]. RBL2 targeting is also seen in ovarian carcinoma via 
overexpression of miR-17/92 paralog miR-106a [38]. RBL2 could be similarly targeted by loss of chr 
16q in PB. However, we did not observe RBL2 mutations in our limited WES, nor that chr 16q loss and 
miR-17/92 gain/amplification were mutually exclusive. Further studies will have to be completed to 
fully characterize the MYC-miR-17/92-RB axis and the role of RBL2 in PB. 
 
Clinical studies of PBs to date have been limited by its rarity and lack of large, disease specific 
prospective cohorts. The recently completed Children’s Oncology Group high-risk EBT trial 
ACNS0332, enrolled 34 patients >3yrs, however separate clinical and molecular analyses of the PB 
cohort has not been reported [29]. Our clinical findings are limited by the retrospective nature of our 
registry-based cohort, and relatively smaller numbers compared to other studies of far more common 
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childhood EBTs. Indeed, only recently have two clinical analyses with larger numbers, both 
retrospective, been published: a single institution study of 41 patients from St. Jude Research Hospital 
[51] and a pooled analysis of 135 patients from SIOP-E and US Head Start trial groups [45]. No 
previous published study has yet performed a combined molecular and clinical analysis as we have 
sought to do here. The clinical applicability of our findings will likely require further validation 
through continued collaboration with other research groups to pool enough data to power subgroup-
specific risk stratification and inform therapy.  
Nonetheless, consistent with prior studies [31,23,40,63,51,45], we identified young age at 
diagnosis (<3 yrs), metastatic disease, and omission of upfront RT as negative prognostic factors for 
PB survival. Also in agreement with published observations [51,45,17] our analysis did not reveal 
prognostic correlations with HDC or extent of surgery across all PB patients, although there was a 
trend toward improved EFS in children <3yrs who received HDC. 
 In contrast to the excellent outcome in group 2 PB (5-yr OS 100%), groups 1 and 3 patients had 
intermediate outcomes (68.0 and 80%), while groups RB and MYC patients had poorest outcomes 
(37.5 and 28%). Metastatic disease and chr 16 loss, which correlate with poorer survival across the 
entire cohort, was also enriched in group 1, RB, and MYC PBs, thus suggesting adverse molecular and 
clinical risk features may account partly for the poorer outcomes of these patients.  
While the difference in EFS and OS between group 2 and 3 is due to just one group 3 patient 
who recurred then died from disease, another group 3 patient was only treated with palliative 
chemotherapy and thus not included in our intent-to-treat analysis. Both patients had extra-CNS (M4) 
metastasis at diagnosis. In contrast, of nine patients with group 2 tumors and clinical data, two were 
excluded from our intent-to-treat analysis: one who refused treatment, and another who died from 
intraoperative complications. No treated patients recurred or died. These differences in clinical features 
between the two groups not captured by intent-to-cure only EFS/OS estimates have led us to assign 
group 2 a superior prognosis to group 3.   
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The impact of different age-related therapeutic approaches likely contributes to differences in 
outcomes across PB patients. Indeed, we observed a significant difference in proportion of patients 
<3yrs (4/11; 36.4%) vs. those ≥3yrs of age at diagnosis (33/36; 91.7%; p<0.001) who received upfront 
RT, suggesting RT avoidance may play a role in adverse outcomes seen in younger patients who 
primarily had group 1, RB and MYC PB. Of note, group 2 and 3 PB had the highest median age at 
diagnosis, including three patients >20yrs of age who were alive at last follow-up after therapy that 
included only up-front RT. In contrast, two adult patients >20yrs at diagnosis who had group 1 and 
MYC tumors, both died despite receiving multimodal therapy including CSI, suggesting intensive 
therapy may not completely negate adverse tumor biology. Despite the prognostic impact of RT 
demonstrated by our study and that of others, it is also interesting to note that 5/29 long term survivors 
in our cohort who never received radiation therapy were young patients with group 1 (2 patients), MYC 
(2 patients), and RB (1 patient) PBs.  
Our integrative molecular and clinico-pathologic analyses in this study which has identified five 
distinct molecular sub-groups of PB has provided important new insights into the pathogenesis of PB 
and confirm the importance of cancer predisposition related to miRNA biogenesis and RB1 gene 
defects in PB patients.  Our study indicates groups 1-3 PBs patients treated with contemporary multi-
modality regimens have intermediate to excellent outcomes but also highlight critical treatment gaps 
for younger PB patients most susceptible to radiation-related toxicities. Although our retrospective 
study has limitations, it represents one of the largest integrated clinical and molecular analyses of PB to 
date and provides new and critical information to inform therapy reduction in prospective clinical trials 
for favorable risk patients and development of novel therapies for high risk patients. 
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Figure and Tables Legends 
 
Figure 1 PB comprise five molecular sub-groups 
a. Flow diagram of analyses performed: 93 primary tumors with institutional diagnosis of 
pineoblastoma (PB) or supratentorial PNET (sPNET) were analysed using global methylation profiling 
and compared against a reference cohort of 1200 pediatric brain tumors to identify and exclude samples 
that segregated with other brain tumors. A cluster of robust, molecularly confirmed 72 PBs were 
further characterized using methylation and SNP arrays for copy number alterations, mutational 
analyses using WES and targeted sequencing, and Nanostring analyses for miRNA expression. 
Clinical, treatment, and molecular sub-group data available for 46 PB patients treated with curative 
intent were integrated for clinic-pathologic analyses.  
b. t-Distributed stochastic neighbour embedding (tSNE) plots of DNA methylation clustering patterns 
of 93 presumed PB samples relative to 951/1200 representative pediatric brain tumor entities 
demonstrate PB clusters separately from other tumor entities. Plots using the top 12,500 most varying 
methylation probes by standard deviation (SD) are shown. Tumors are shown as colored spheres which 
include atypical teratoid rhabdoid tumor (ATRT), ependymoma posterior-fossa (EP_PF) or 
supratentorial, RELA-fusion (EP_RELA), embryonal tumor multiple rosettes (ETMR), germ cell tumor 
(GCT), high-grade glioma (HGG), neuroblastoma (NB), medulloblastoma WNT (MB_WNT), SHH 
(MB_SHH), group 3 (MB_G3), and group 4 (MB_G4). Black spheres indicate tumors with an 
institutional diagnosis of PB that segregated with other known brain tumor entities are (n=21). A robust 
cluster of 72 PBs is boxed; blow-up image of PB cluster on right shows five molecular PB sub-groups 
designated as 1, 2, 3, RB, and MYC.  
 
Figure 2 PB molecular subgroups have distinct copy number landscapes 
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a. Pattern of copy number alterations across PB molecular sub-groups as determined using GISTIC 
analyses of global methylation data. Chromosomal regions with recurrent copy number gains (green) or 
losses (red) significantly enriched within each PB sub-group are highlighted; asterisk indicates false 
discovery rate of q<0.05.  
b, c. Composite circos plots of global methylation profiles showing recurrent copy number gains 
(green) and losses (red) in 21 group 1 and 11 group 2 PBs. Focal or broad alterations associated with 
miRNA biogenesis loci DICER1, DROSHA and DGRC8 are highlighted. Higher resolution copy 
number profiles generated using Conumee, of representative group 1 and group 2 samples with 
respective focal chr 5p13.3 targeting DROSHA and chr 14q loss associated with DICER1, are shown on 
the right.  
 d. Composite circos plot of global methylation profiles in 13 group 3 PBs. Higher resolution copy 
number profile generated using Conumee of a representative group 3 sample is shown on right.  
 
Figure 3 Recurrent copy number alterations in RB and MYC sub-group PBs 
a. Composite circos plot of global methylation profiles from 9 RB subgroup PBs depicting recurrent 
copy number gains (green) and losses (red); recurrent copy number alterations associated with miR-
17/92 and RB1 are highlighted. Higher resolution copy number profile of a representative tumor RBTC 
1546 with homozygous loss of RB1 at chr13q14.2 and copy number gain encompassing miR-17/92 at 
chr 13q31.3 is shown on right.  
b. Copy number driven expression of miR-17/92 in RB sub-group PB. MiRNA expression levels for 
the miR-17-92, paralogous miR106a-363, miR-106b-25 and unrelated let-7 loci was determined from 
NanoString(v.3) miRNA expression data from 6 PBs. Plots show relative, normalized probe intensities 
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of miRNAs in PB sub-groups; miRNA expression levels of RBTC746 with focal chr13q13.3 copy 
number gains targeting miR-17-92 shown in Figure A, is highlighted.  
c.  Composite circos plot of global methylation profiles from 18 MYC subgroup PBs. Recurrent focal 
chr 8q amplification/gains (green) and chr 16q losses (red) are highlighted. Higher resolution copy 
number profile of a representative tumor, RBTC 1520, with focal MYC amplification is shown on right. 
 
Figure 4 Recurrent mutations/alterations of miRNA biogenesis genes, RB1 and MYC characterize 
PB sub-groups.  
a. Summary of mutations and copy number alterations associated with miRNA biogenesis gene 
(DICER1, DROSHA, DGCR8, XPO5, TARBP2), KBTBD2, RB1, miR-17/92, and MYC determined 
using a combination of targeted sequencing, WES,  methylation and SNP array based copy number 
analyses in individual PBs of different sub-groups with tumor and matched blood DNA available for 
study. Samples lacking materials for specific assay are indicated by (-); broad copy number alterations 
determined by methylation or SNP-based copy number analyses are indicated by HT (heterozygous), 
HM (homozygous), n (normal diploid) or presence (Y) of MYC focal gains or amplification (α) is 
indicated. Status or specific gene alterations determined by targeted sequencing or WES is indicated as 
wt (wild-type); * (stop-gain mutation), fs (frameshift insertion or deletion), † (deleterious missense 
mutation predicted by SIFT and Polyphen2). All predicted truncating gene mutations are highlighted.  
b. Schema of DICER1 and DROSHA mutations relative to maps of corresponding proteins. Type and 
location of mutations are shown as colored symbols relative to amino acid sequence numbers and 
known or predicted functional domains; colors of mutation symbols correspond to tumor sub-group.  
 
Figure 5 Molecular sub-groups of PB have distinct clinicopathologic features 
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a. Scatterplot of age at diagnosis for PB patients relative to tumor molecular sub-group. Bar indicates 
median age as determined using Kruskal-Wallis test.  
b. Frequency of metastatic (M+; M1, -3, -4) and non-metastatic (M0) disease determined as per the 
Chang staging system is shown relative to PB sub-groups; significance in distribution of M+ versus M0 
patients across all PB sub-groups was determined using Fisher exact test.  
c. Forest plot of Hazard ratio (HR) from univariate Cox proportional hazards regression model of 
gender (male/M vs. female/F), age, metastatic status (M+ vs M0), radiotherapy (no upfront RT vs. 
upfront RT), conventional chemotherapy only (chemo) vs. high-dose chemotherapy (HD), and extent 
of tumor removal (less than gross total resection/GTR vs GTR) on EFS (black) and OS (gray) was 
performed on data from 46 patients treated with curative intent. Whiskers denote 95% confidence 
interval.  
d. Kaplan-Meier survival analyses of event free (EFS) and overall survival (OS) for 46 patients treated 
with curative intent stratified by PB sub-groups. Plots abbreviated to maximum of 12 years from 
diagnosis. For patients with group 1-3, RB, and MYC PBs EFS were respectively, 39.5%, 100%, 
83.3%, 25.0%, and 14.3%; 5-year OS were 68.0%, 100%, 80%, 37.5%, and 28.6%.  
 
Figure 6 Schematic summary of molecular and clinical features across PB sub-groups 
 
Table 1 Summary of PB mutations identified in this study 
 
Table 2 Summary of patient features and treatment across PB sub-groups 
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Supplementary Figures and Tables, online resource 
 
Supplementary Figure 1 PBs comprise 5 molecular sub-groups 
Global methylation data generated from 72 PBs using Illumina 450K or EPIC arrays were analysed 
using NMF, HCL and K-means clustering methods to identify molecular sub-groups.  
a. Non-matrix factorization (NMF) analyses was performed on global methylation data using top 5000-
15, 000 DNA methylation probes as determined by standard deviation (SD). Highest co-phonetic score 
was determined at rank (k) = 5 with 5000 probes; corresponding NMF heat map generated with 5000 
probes is shown with PB sub-group designation. 
b. Silhouette plot of NMF analysis indicating best fit of individual PB sample within molecular sub-
group  
c. Hierarchal (HCL) and K-means cluster analyses of global methylation data using the 5000 most 
variable probes by standard deviation indicating 5 sub-groups of PBs  
 
Supplementary Figure 2 SNP array copy number analyses of PB 
Copy number calls were generated using ASCAT (Allele specific copy number analysis of tumor) on 
Illumina Omni SNP array data generated from PBs  
a. ASCAT for group 2 tumor RBTC814 showing homozygous chr 14 loss  
b. ASCAT plot for group RB tumor RBTC746 showing homozygous RB1 loss and gain of miR-17/92. 
 
Supplementary Figure 3 Schematic of hotspot mutations in Kelch domain of KBTBD4 
a. IGV screenshot of aligned reads from whole exome sequencing of RBTC786 and -793 
demonstrating in-frame insertions in KBTBD4, resulting in identical p.P311_R312 duplication 
mutation. Comparison is made to the same mutation reported by Lee JC, et al. 2019. 
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b. Mapped in-frame insertions (in yellow) in our cohort, compared to those described by Lee JC, et al. 
in three PPTID samples, which are identical to that seen in RBTC793. All mutations result in the same 
p.P311_R312 duplication mutation. 
 
Supplementary Figure 4 Impact of age, metastatic status and radiation treatment on PB survival  
Event free (EFS) and overall survival (OS) analyses were determined for 46 patients treated with 
curative intent, using the Kaplan-Meier method and log rank tests.  
a. EFS and OS of patients <3 or ≥3 years age at diagnosis. 5-yr EFS: 18.2 vs 58.2%; 5-yr OS: 24.2 vs. 
77.0% for <3 yrs vs. ≥3 yrs. 
b. EFS and OS of patients without (M0) and with metastases (M+) at diagnosis. 5-yr EFS: 29.4 vs. 
60.5%; 5-yr OS: 44.9 vs. 78.7% for M+ vs. M0. 
c. EFS and OS of patients treated with and without upfront radiation therapy. 5-yr EFS: 10.0 vs. 58.8%; 
5-yr OS: 40.0 vs. 71.0% for not radiated vs. radiated. 
 
Supplementary Figure 5 Impact of chr 16 loss on event free and overall survival of PB survival  
Event-free (EFS) and overall survival (OS) analyses were determined for 46 patients treated with 
curative intent, stratified by chr 16 loss or no chr 16 q loss in tumor specimens, using the Kaplan-Meier 
method and log rank tests. 5-yr EFS: 17.6 vs. 61.1%; 5-yr OS: 52.1 vs. 70.0% for chr 16q loss vs. no 
loss. 
 
Supplementary Table 1 Molecular analysis performed on tumors and blood samples 
 
Supplementary Table 2 Reported Ki67/MIB-1 scores and presence of hotspot KBTBD4 mutation 
among PB 
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● Ependymoma, RELA fusion
● ETMR
● Germ cell tumor
● High-grade glioma
● MB group 3
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20 no treatment info
4 palliative
1 refused treatment
Cases with surgical, radiation, 
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717 S1585* S1585*, R509* n P67T P67T n wt wt n wt wt wt wt - wt wt n n n
767 - Y1701* n - wt n - wt HT - wt - wt - - wt n n n
712 - Y1701* HT - wt n - wt n - wt - wt - - wt n n n
745 Y1701* Y1701* HT wt wt n wt wt n wt wt wt wt - wt wt n n n
716 D1810fs D1810fs, S1158fs n wt wt n wt wt n I1111 I1111M wt wt - wt wt n n n
1216 wt S1101fs n wt wt n wt wt n wt wt wt wt - wt wt n n n
777 - wt n - H549fs, X1221splice n - wt n - wt - wt - - wt n n n
773 - wt n - wt HM - wt n - wt - wt - - wt n n n
776 - wt n - wt HM - wt n - wt - wt - - wt n n n
775 - wt n - wt HM - wt HT - wt - wt - - wt n n n
771 - wt n - wt n - S92fs HT - wt - wt - - wt n n n
801 - wt n - wt n - G509R HT - wt - wt - - wt n n n
757 - - n - - n - - HT - - - - - - - n n n
718 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n n
787 - wt n - wt n - wt n - wt - wt - - wt n n n
794 - wt n - wt n - wt n - wt - wt - - wt n n n
789 - wt n - wt n - wt n - wt - wt wt - wt n n Y
1367 - wt n - wt n - wt n - wt - wt - - wt n n n
751 - wt n - wt n - wt n - wt - wt - - wt n n n
763 - - n - - n - - n - - - - - - - n n n
1088 - - n - - n - - n - - - - - - - n n n
715 wt Y1121* HT wt wt n wt wt n wt wt wt wt - wt wt n n n
797 - Y1121* HT - wt n - wt n - wt - wt - - wt n n n
724 - 571KFK, Y543N HT - wt n - D248N HT - wt - wt - - wt n n n
723 D294fs D294fs HT wt wt n wt wt n wt wt wt wt - wt wt n n n
781 - F537fs HT - wt n - wt n - wt - wt - - wt n n n
782 - S1618fs HT - wt n - wt n - wt - wt - - wt n n n
1222 wt P642fs HT wt wt n wt wt n wt wt wt wt wt wt wt n n n
803 D1810fs D1810fs HT P152L n wt HT wt wt - wt n n n
814 - wt HT - Q163* n - wt n - wt - wt - - wt n n n
780 - wt n - P1072fs, R252* n - wt n - wt - wt - - wt n n n
792 - wt n - wt HM - wt n - wt - wt wt - wt n n n
785 - wt n - wt n - wt n - wt - wt - - wt n n n
784 - wt n - wt n - wt n - wt - wt - wt HM n nwt
765 - wt n - wt n - wt n - wt - wt - wt HT n nwt
788 - wt n - wt n - wt n - wt - wt - wt HT n nwt
786 - wt n - wt n - wt n - wt - wt - wt n n n
793 - wt n - wt n - wt n - wt - wt - wt n n n
799 wt wt n wt wt n wt wt n wt wt wt wt wt wt n n n
1110 - wt n - wt n - wt n - wt - wt - wt n n n
1221 wt wt n wt wt n wt wt n wt wt wt wt wt wt n n n
877 - wt n - - n - - n - - - - - - - n n n
742 - - n - - n - - n - - - - - - - n n n
1781 - - n - - n - - n - - - - - - - n n n
783 - n - - n - - n - - - - - - - n n n
1360 - wt n - wt n - wt n - wt - wt - - R320* n n n
1231 - wt n - wt n - wt n - wt - wt - - R320* n n n
758 wt S1747L n wt K939N n wt wt n wt P905L wt wt - wt Q121* HT Y n
734 - wt n - wt n - wt n - wt - wt - - wt HM Y n
746 wt wt n - wt n - wt n - wt - wt - - wt HM Y n
1546 wt wt n wt wt n wt wt n wt wt wt wt - wt wt HM Y n
1518 wt wt n wt wt n wt wt n wt wt wt wt - wt wt HM n n
1543 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n n
1533 wt - n wt - n wt - n wt - wt - - wt - n n n
1520 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n Y
1527 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n Y
778 - wt n - wt n - wt n - wt - wt - - wt n n Y
779 - R490C n - wt n - wt n - wt - wt - - wt n n Y
748 wt wt n - wt n - wt n - wt - wt - - wt n n Y
1086 - wt n - wt n - wt n - wt - wt - - wt n n Y
1503 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n Y
764 - - n - - n - - n - - - - - - - n n Y
1016 - - n - - n - - n - - - - - - - n n Y
736 - wt n - wt n - wt n - wt - wt - - wt n n n
738 - wt n - wt n - wt n - wt - wt - - wt HM n n
750 - wt n - wt n - wt n - wt - wt - - wt n n n
795 - wt n - wt n - wt n - wt - wt - - wt n n n
1525 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n n
1522 wt wt n wt wt n wt wt n wt wt wt wt - wt wt n n n
881 - wt n - - n - - n - - - - - - - n n n
769 - - n - - n - - n - - - - - - - n n n
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Gender (M:F) 1 : 1.1 1 : 1.75 1 : 1.1 1 : 3.5 2.6 : 1






















Cancer types in COSMIC
Y1701* Nonsense Truncating 3 1 Liver
S1585* Nonsense Truncating 1 Novel
R509* Nonsense Truncating 1 3 Melanoma
Y1121* Nonsense Truncating 2 Novel
D1810fs Frameshift indel Truncating 2 Novel
S1158fs Frameshift indel Truncating 1 Novel
S1101fs Frameshift indel Truncating 1 Novel
D294fs Frameshift indel Truncating 1 Novel
F537fs Frameshift indel Truncating 1 Novel
S1618fs Frameshift indel Truncating 1 Novel
P642fs Frameshift indel Truncating 1 Novel
Y543N Missense Altered helicase domain 1 Novel
S1747L Missense Altered RNase IIIb domain 1 2 Breast
R490C Missense Helicase Domain † 1 1 Bladder
571_573delinsKFK Missense Helicase Domain - unknown 1 Novel
Q163* Nonsense Truncating 1 Novel
R252* Nonsense Truncating 1 Novel
H549fs Frameshift indel Truncating 1 Novel
P1072fs Frameshift indel Truncating 1 Novel
X1221_splice Splice site Truncating 1 Novel
P152L Missense Not in functional domain † 1 Novel
P67T Missense Not in functional domain † 1 1 Large intestine
K939N Missense Altered RNase IIIa domain 1 1 Breast





D248N Missense Not in functional domain † 1 Novel
I1111M Missense Unknown † 1 Novel
P905L Missense Unknown † 1 Novel
R320* Nonsense Truncating 2 21 Retinoblastoma, endometrial, breast
Q121* Nonsense Truncating 1 2 Lung, thyroid
KBTBD4 p.P311_R312dup In-frame insertion Altered Kelch binding domain 2 0 PPTID a, MB b



















Table 2 Summary of patient features and treatment across PB sub-groups 
n % n % n % n % n % n %
Number of patients 72 21 29 11 15 13 18 9 13 18 25 p-value
Gender 72 21 11 13 9 18 0.127
Male 36 50 10 48 4 36 7 54 2 22 13 72
Female 36 50 11 52 7 64 6 46 7 78 5 28
Age 61 21 11 11 5 13 <0.0001 *
Median (yrs) (range) 6.5 (0.5-60)
<1 3 5 0 0 0 0 0 0 0 0 3 23
1 to <3 14 23 3 14 1 9 0 0 4 80 6 46
3 to <10 20 33 14 67 1 9 2 18 1 20 2 15
10 to <18 16 26 2 10 7 64 6 55 0 0 1 8
≥18 8 13 2 10 2 18 3 27 0 0 1 8
Stage 54 21 8 8 5 12 0.028 *
M0 33 61 13 62 7 88 6 75 0 0 7 58
M+ 21 39 8 38 1 12 2 25 5 100 5 42
Surgery 47 21 7 7 4 8 0.431
GTR 17 36 5 24 3 43 4 57 1 25 4 50
<GTR 30 64 16 76 4 57 3 43 3 75 4 50
Radiotherapy 47 21 7 7 4 8 0.041 *
Yes 37 79 17 81 7 100 7 100 2 50 4 50
No 10 21 4 19 0 0 0 0 2 50 4 50
Chemo 46 21 7 6 4 8 0.749
HDC 29 63 15 71 4 57 3 50 3 75 4 50
Conventional 17 37 6 29 3 43 3 50 1 25 4 50
Status 47 21 7 7 4 8 0.019 *
Dead 18 38 9 43 0 0 1 14 2 50 6 75
Alive 29 62 12 57 7 100 6 86 2 50 2 25
Recurrence 46 21 7 7 4 7 0.003 *
Yes 21 46 12 57 0 0 1 14 2 50 6 86







































































































1.3 (1.1-3.3) 1.4 (0.5-21.0)
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RBTC814 - group 2 tumor
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1413121110987654321 15 16 17 18 19 20 21 XY
1413121110987654321 15 16 17 18 19 20 2122 X Y
22
















DNA base # 947 946 945 944 943 942 941 940 939 938 937 936 935 934 933 932 931 930
Position in chr 11 47595139 47595140 47595141 47595142 47595143 47595144 47595145 47595146 47595147 47595148 47595149 47595150 47595151 47595152 47595153 47595154 47595155 47595156
C T T C C A C A T G C G C C G T G G
RBTC786 C A T G C G C C G T G G G C G T G G
Complementary G T A C G C G G C A C C C G C A C C
RBTC793 C A T G C G C C G T G G C C G T G G
Complementary G T A C G C G G C A C C G G C A C C
C A T G C G C C G T G G C C G T G G
G T A C G C G G C A C C G G C A C C
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746 PB PB Yes - Yes Yes -
748 PB PB Yes - Yes Yes Yes
718 PB PB Yes - Yes - -
723 PB PB Yes - Yes - -
803 PB PB Yes - Yes - -
1216 sPNET PB Yes - Yes - -
1525 PB PB Yes - Yes - -
1527 PB PB Yes - Yes - -
1543 PB PB Yes - Yes - -
1546 PB PB Yes - Yes - -
1503 PB PB Yes - Yes - -
1518 PB PB Yes - Yes - -
1520 PB PB Yes - Yes - -
1522 PB PB Yes - Yes - -
715 PB PB Yes - Yes - -
716 PB PB Yes - Yes - -
717 PB PB Yes - Yes - -
758 PB PB Yes - Yes - -
745 PB PB Yes - Yes - -
814 sPNET PB Yes - - Yes -
742 PB PB Yes - - Yes -
750 PB PB Yes - - Yes -
734 PB PB Yes - - - -
736 PB PB Yes - - - -
738 PB PB Yes - - - -
771 PB PB Yes - - - -
773 PB PB Yes - - - -
775 PB PB Yes - - - -
776 PB PB Yes - - - -
777 PB PB Yes - - - Yes
778 PB PB Yes - - - -
780 PB PB Yes - - - -
787 PB PB Yes - - - -
794 PB PB Yes - - - -
795 PB PB Yes - - - -
801 PB PB Yes - - - -



















1360 sPNET PB Yes - - - -
712 sPNET PB Yes - - - -
724 PB PB Yes - - - -
767 PB PB Yes - - - -
779 PB PB Yes - - - -
781 PB PB Yes - - - -
782 PB PB Yes - - - -
785 PB PB Yes - - - -
797 PB PB Yes - - - -
877 PB PB Yes - - - Yes
881 sPNET PB Yes - - - -




PB Yes - - - -
1221 PPTID PB - Yes Yes - -
799 PB PB - Yes Yes - -
784 PB PB - Yes - - Yes
788 PB PB - Yes - - -
1110 PB PB - Yes - - -
1222 PB PB - Yes Yes - -
786 PB PB - Yes - - -
793 PB PB - Yes - - -
765 PPTID PB - Yes - - -
789 PB PB - Yes - - -
792 PB PB - Yes - - -
1533 PB PB - - Yes - -
751 PB PB - - - Yes -
1781 sPNET PB - - - - Yes
757 PB PB - - - - -
761 PB PB - - - - -
763 PB PB - - - - -
764 PB PB - - - - Yes
769 PB PB - - - - -
783 PB PB - - - - -
1016 sPNET PB - - - - -



















RBTC716 PB 1 "Very high" n/a
RBTC717 PB 1 >20 n/a
RBTC718 PB 1 >50 n/a
RBTC745 PB 1 >75 n/a
RBTC771 PB 1 51.5 n/a
RBTC776 PB 1 >50 n/a
RBTC777 PB 1 40-60 n/a
RBTC787 PB 1 30-40 n/a
RBTC775 PB 1 40-80 n/a
RBTC773 PB 1 30-50 n/a
RBTC715 PB 2 Mixed low and high areas n/a
RBTC723 PB 2 "Very high" n/a
RBTC803 PB 2 10-15 n/a
RBTC1222 PB 2 30-40 Absent
RBTC780 PB 2 25 n/a
RBTC781 PB 2 25 n/a
RBTC782 PB 2 >40 n/a
RBTC792 PB 2 50 Absent
RBTC797 PB 2 15 n/a
RBTC742 PB 3 n/a n/a
RBTC765 PPTID 3 3 Absent
RBTC783 PB 3 40 n/a
RBTC784 PB 3 10 Absent
RBTC785 PB 3 n/a n/a
RBTC786 PB 3 10 Present
RBTC788 PB 3 25 Absent
RBTC793 PB 3 15 Present
RBTC799 PB 3 15 Absent
RBTC877 PB 3 n/a n/a
RBTC1110 PB 3 n/a Absent
RBTC1221 PPTID 3 15 Absent
RBTC1781 sPNET 3 n/a n/a
RBTC779 PB MYC 40 n/a
RBTC758 PB RB n/a n/a
Ki67/MIB-1 proliferation indices/scores were retrieved from pathology reports from original institutio
For scores given in ranges, the mean value was used for any subsequent analyses.
Supplementary Table 2 (online resource): Ki67/MIB-1 scores and presence of hotspot 
KBTBD4  mutation among PB and PPTID

























712 PNET PB 1 Temporal 0 2.0 M 244 N 244 Alive STR CSI HD Y
716 PB PB 1 Pineal 3 6.7 F 8 N 8 Dead Biopsy CSI HD Y
717 PB PB 1 Pineal 0 3.0 M 96 N 96 Alive STR CSI HD Y
718 PB PB 1 Pineal 0 3.3 M 144 N 144 Alive STR CSI HD Y
745 PB PB 1 Pineal 0 3.3 F 59 Y 76 Dead STR CSI HD Y




757 PB PB 1 Pineal 3 6.7 F 69 Y 125 Dead STR CSI HD Y
763 PB PB 1 Pineal 0 2.0 F 10 Y 16 Dead GTR No HD Y
767 PB PB 1 Pineal 0 5.2 M 101 N 101 Alive GTR CSI HD Y
771 PB PB 1 Pineal 3 4.2 F 26 Y 49 Dead STR CSI Standard Y
773 PB PB 1 Pineal 0 19.0 F 35 Y 56 Alive GTR CSI HD Y
775 PB PB 1 Pineal 3 13.3 M 61 N 61 Alive Biopsy CSI HD Y
776 PB PB 1 Pineal 0 8.7 F 3 Y 27 Dead STR No HD Y
777 PB PB 1 Pineal 3 4.8 M 58 Y 75 Dead STR Focal Standard Y
787 PB PB 1 Pineal 0 3.0 M 18 Y 33 Alive STR Focal HD Y
789 PB PB 1 Pineal 0 9.5 M 18 Y 50 Dead STR CSI Standard Y
794 PB PB 1 Pineal 3 41.5 F 24 Y 25 Dead GTR CSI Standard Y
801 PB PB 1 Pineal 3 6.8 F 73 N 73 Alive STR CSI HD Y
1088 PB PB 1 Pineal 0 3.5 M 53 N 53 Alive Biopsy CSI HD Y
1216 sPNET PB 1 Pineal 3 2.0 M 12 Y 14 Alive GTR No HD Y
1367 PB PB 1 Pineal 0 5.3 F 2 Y 61 Alive STR No Standard Y
715 PB PB 2 Pineal 0 12.5 F 77 N 77 Alive STR CSI HD Y
723 PB PB 2 Pineal 0 11.6 F 61 N 61 Alive GTR CSI HD Y
724 PB PB 2 Pineal 0 1.3 F n/a n/a n/a n/a n/a n/a n/a n/a
780 PB PB 2 Pineal 3 8.4 M 121 N 121 Alive STR CSI Standard Y
781 PB PB 2 Pineal 0 12.7 F 91 N 91 Alive STR Focal HD Y
782 PB PB 2 Pineal 0 31.0 F 79 N 79 Alive Biopsy CSI Standard Y
792 PB PB 2 Pineal n/a 31.5 M n/a n/a n/a n/a n/a n/a No n/a
797 PB PB 2 Pineal 0 13.3 M 40 N 40 Alive GTR CSI HD Y
803 PB PB 2 Pineal 0 12.3 F 23 N 23 Alive GTR CSI Standard Y
814 PNET PB 2 n/a n/a 12.0 M n/a n/a n/a Dead n/a n/a n/a N
1222 PB PB 2 Pineal n/a 13.9 F 6 Y 6 Alive GTR No No N
742 PB PB 3 Pineal n/a 11.0 M n/a n/a n/a n/a n/a n/a n/a n/a
765 PPTID PB 3 Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
783 PB PB 3 Pineal 4 12.6 M 13 Y 14 Dead Biopsy No Standard N
784 PB PB 3 Pineal n/a 60.0 M 66 N 66 Alive STR Focal Standard Y
785 PB PB 3 Pineal 0 4.4 F 33 N 33 Alive GTR CSI HD Y





























788 PB PB 3 Pineal n/a 29.2 M n/a n/a n/a n/a n/a n/a No n/a
793 PB PB 3 Pineal 0 16.0 M 27 N 27 Alive GTR CSI HD Y
799 PB PB 3 Pineal 4 11.6 M 22 Y 29 Dead Biopsy CSI HD Y
877 PB PB 3 Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
1110 PNET PB 3 Pineal 0 3.5 M 137 N 137 Alive STR CSI Standard Y
1221 PPTID PB 3 Pineal 0 15.7 F 14 N 14 Alive GTR CSI Standard Y




PB MYC Pineal 0 0.8 F 5 N 5 Dead STR No Standard N
738 PB PB MYC Pineal 0 21.0 F 47 Y n/a Dead GTR CSI HD Y
748 PB PB MYC Pineal 3 0.5 F 7 Y 10 Dead n/a No Standard n/a
750 PB PB MYC Pineal n/a 1.0 M n/a n/a n/a n/a n/a n/a n/a n/a
761 PB PB MYC Pineal 0 1.3 M 0 N 0 Dead "Radical" No No N
764 PB PB MYC Pineal 3 5.0 M 1.5 Y 204 Alive STR No Standard Y
769 PB PB MYC Pineal 3 1.0 M 33 Y 34 Dead Biopsy No HD Y
778 PB PB MYC Pineal 0 1.5 M 28 Y 42 Dead GTR Focal Standard Y




PB MYC Pineal 0 1.4 M 8 Y 9 Dead STR Focal HD Y
881 PNET PB MYC Pineal 0 11.8 M 0 N 0 Dead n/a No No n/a




1086 PNET PB MYC Pineal 0 0.9 M 165 N 165 Alive GTR No HD Y
1503 PB PB MYC Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
1520 PB PB MYC Pineal n/a n/a M n/a n/a n/a n/a n/a n/a n/a n/a
1522 PB PB MYC Pineal n/a n/a M n/a n/a n/a n/a n/a n/a n/a n/a
1525 PB PB MYC Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
1527 PB PB MYC Pineal n/a n/a M n/a n/a n/a n/a n/a n/a n/a n/a
734 PB PB RB Pineal 3 2.3 M 10 Y 34 Dead STR CSI HD Y
746 PB PB RB Pineal 3 1.1 F 10 N 10 Dead n/a No Standard n/a




PB RB Pineal 3 1.2 F 14 Y 14 Alive GTR No HD Y
1360 sPNET PB RB Pineal 3 1.2 M 2.4 N 2.4 Dead STR No Standard Y
1518 PB PB RB Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
1533 PB PB RB Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
1543 PB PB RB Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
1546 PB PB RB Pineal n/a n/a F n/a n/a n/a n/a n/a n/a n/a n/a
